GlucoTrack Inc (GCTK) News

Form 8-K - Current report

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 8-K - Current report

Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering

Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE

Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING

Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology...